WASHINGTON (AP) — The maker of a drug for Lou Gehrig’s disease that recently failed in a large study said Thursday it will pull the medicine from the market, acknowledging it didn’t help patients with the deadly neurological condition.
Amylyx Pharmaceuticals announced it will voluntarily halt sales and marketing of the drug in the U.S. and Canada, where new patients will no longer be able to get a prescription.
“While this is a difficult moment for the ALS community, we reached this path forward in partnership with the stakeholders who will be impacted and in line with our steadfast commitment to people living with ALS,” company co-founders said in a statement. Patients already taking the therapy who wish to continue will be able to enroll in a program to receive it for free.
The Food and Drug Administration approved the much-debated drug, Relyvrio, in September 2022, following a years-long advocacy campaign by patients with amyotrophic lateral sclerosis, or ALS.
Related articles:
Related suggestion:
Experts tout 6G's industrial potential at Hannover trade fairBoosted by sciChina embraces AI boom, diverse application scenariosAntiques Roadshow guest shocked by astonishing value of medieval stone head she found in her DRAINBarcelona's De Jong out for season, ready for EurosChina calls for solidarity, cooperation to create better future for Asia, worldWinning farewell for China at U23 Asian CupIsrael says building of Gaza aid pier beginsYou don't need great legs, good skinWinning farewell for China at U23 Asian Cup
2.446s , 6500.90625 kb
Copyright © 2024 Powered by Why Amylyx is pulling ALS drug Relyvrio from US market after study ,World Wonders news portal